TICKERNERD
Menu
INSPINSPHealthcare · Medical Devices

INSP Stock Forecast: Inspire Medical Systems, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$69
−0.36% on the day

The 17 Wall Street analysts covering Inspire Medical Systems, Inc. hold a median 12-month price target of $60 — -12.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 23 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$2.0B
Ticker Nerd rank
84 / 100
Median analyst target
$60
Analysts covering
17
Revenue$200.6M−7.6% y/y
Operating income−$514K
Net income$314K
Free cash flow$14.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.4%
1M
+11.9%
YTD
−25.4%
1Y
−11.6%
From 52W high
−52.2%
From 52W low
+71.8%
$40
$144
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inspire Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
95
Issuance
86
Revisions
82
Volatility
74
Growth
64
Size
36
Accruals
26
Momentum
21

Quality (99): The business earns solid, repeatable profits on what it owns.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26INSPHigh $97Median $60Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
4 Buy11 Hold2 Sell
Low $40Median $60High $97

The green dot is the last close — the median target sits −12.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
21 Sept 2026Freedom Capital MarketsMaintainsBuy$71 → $97
11 Sept 2026StifelMaintainsBuy—
11 Sept 2026StifelMaintainsBuy$75 → $80
4 Aug 2026BairdMaintainsNeutral$54 → $59
4 Aug 2026BairdMaintainsNeutral—
4 Aug 2026Evercore ISI GroupMaintainsIn-Line—
4 Aug 2026Evercore ISI GroupMaintainsIn-Line$40 → $54
4 Aug 2026JP MorganMaintainsNeutral$54 → $60
4 Aug 2026JP MorganMaintainsNeutral—
4 Aug 2026MizuhoMaintainsOutperform—
4 Aug 2026MizuhoMaintainsOutperform$55 → $65
4 Aug 2026OppenheimerUpgradeOutperform—
4 Aug 2026OppenheimerUpgradeOutperform$85
4 Aug 2026Piper SandlerMaintainsNeutral—
4 Aug 2026Piper SandlerMaintainsNeutral$55 → $60
4 Aug 2026Truist SecuritiesReiteratesHold—
4 Aug 2026Truist SecuritiesReiteratesHold$54 → $62
28 July 2026UBSAssumesSell$67 → $39
16 July 2026Truist SecuritiesMaintainsHold—
16 July 2026Truist SecuritiesMaintainsHold$50 → $54

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Inspire Medical Systems, Inc. returned −11.6% against +17.3% for the S&P 500, dividends included.

INSP vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26INSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+40.0%
Analysts raising
12
Analysts cutting
0
Fundamentals

Inspire Medical Systems, Inc. (INSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.7×

Cheaper than 42% of US stocks

Price / sales
2.2×

Cheaper than 47% of US stocks

Price / book
2.4×

Cheaper than 36% of US stocks

EV / EBITDA
23.9×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
−7.6%

Higher than 18% of US stocks

Earnings growth (YoY)
—
Gross margin
85.5%

Higher than 94% of US stocks

Operating margin
−0.3%

Higher than 32% of US stocks

Net margin
15.0%

Higher than 78% of US stocks

Returns & dividend
Return on equity
18.0%

Higher than 79% of US stocks

Return on assets
3.9%

Higher than 70% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Inspire Medical Systems, Inc. (INSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inspire Medical Systems, Inc. has a market value of $2.0B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $898.7M. The latest quarter shrank 7.6% year on year.

  • Net income over the same four quarters: $135.0M, a 15.0% net margin.

  • Diluted earnings per share, trailing twelve months: $4.62.

  • Free cash flow in the twelve months to 30 June 2026: $117.1M, after $40.0M of capital spending.

  • Inspire Medical Systems, Inc. spent $100.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 28.9M.

  • Trailing P/E: 15.7×; forward P/E: 44.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Inspire Medical Systems, Inc. employs 1,333 people — $674K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

INSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INSPInspire Medical Systems, Inc.$2.0B
84
ESTAEstablishment Labs Holdings, Inc.$2.0B
74
NVCRNovoCure Ltd.$1.9B
96
ALMRAlamar Biosciences, Inc. (California)$2.2B
4
UFPTUFP Technologies, Inc.$2.2B
80
BFLYButterfly Network, Inc.$2.5B
73
AXGNAxoGen, Inc.$2.5B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inspire Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INSP news & analysis

Here's Why You Should Retain INSP Stock in Your Portfolio for Now

Zacks Investment Research · 23 Sept 2026positive

Zacks Investment Research recommends retaining Inspire Medical Systems (INSP) stock as the company navigates a major product transition. The report cites clinical evidence, patient access efforts, and reimbursement progress as factors supporting its growth prospects.

Why it matters — This update signals to INSP watchers that the company's growth outlook is backed by clinical, access, and reimbursement developments during a significant product transition.

Zacks Industry Outlook Medical Systems, American Well and Butterfly Network

Zacks Investment Research · 14 Sept 2026neutral

Zacks published an Industry Outlook article highlighting Medical Systems, American Well, and Butterfly Network. The piece draws attention to these companies within the medical systems sector.

Why it matters — Industry coverage of medical systems companies offers context for broader sector conditions, though Inspire Medical Systems is not specifically referenced in this article.

3 Medical Info Systems Stocks to Gain From GenAI Boom Amid Cyber Risk

Zacks Investment Research · 11 Sept 2026positive

A Zacks Investment Research article identifies INSP, along with AMWL and BFLY, as medical information systems stocks positioned to gain from digital health and GenAI demand, while noting the presence of cybersecurity risks in the sector.

Why it matters — A INSP watcher would care because the article highlights Inspire as one of the stocks expected to benefit from growth in digital health and AI demand, which could shape investor perception of the company.

Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?

Zacks Investment Research · 2 Sept 2026neutral

Zacks Investment Research highlights that Inspire Medical Systems (INSP) reported earnings 30 days ago and has since declined 4.1%. The article examines what may come next for the stock following the earnings report.

Why it matters — INSP watchers would care because the piece addresses the stock's post-earnings performance and potential factors shaping its outlook.

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 26 Aug 2026neutral

Inspire Medical Systems, Inc. announced that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The company is a medical technology firm focused on minimally invasive solutions for obstructive sleep apnea.

Why it matters — Investors and analysts following INSP will have an opportunity to hear directly from its management at a major industry conference, which can provide insight into the company's strategy and outlook.

FAQ

Frequently asked questions about INSP stock

What is the INSP stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Inspire Medical Systems, Inc. have a median 12-month price target of $60, with estimates ranging from $40 to $97. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INSP stock a buy right now?

Of the 17 analysts covering Inspire Medical Systems, Inc., 4 rate it a Buy, 11 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Inspire Medical Systems, Inc. 84 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INSP?

As at 23 Sept 2026, Inspire Medical Systems, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will INSP stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies -12.8% from the last close, and Ticker Nerd's factor model ranks Inspire Medical Systems, Inc. 84 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INSP stock forecast for 2030?

No analyst covering Inspire Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $97 over the next 12 months.

How has INSP stock performed over the past year?

Inspire Medical Systems, Inc. returned -11.6% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inspire Medical Systems, Inc. do?

Inspire Medical Systems, Inc. is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea.

What is the latest news on INSP?

The most recent item we track (Zacks Investment Research, 23 Sept 2026): "Here's Why You Should Retain INSP Stock in Your Portfolio for Now". Zacks Investment Research recommends retaining Inspire Medical Systems (INSP) stock as the company navigates a major product transition. The report cites clinical evidence, patient access efforts, and reimbursement progress as factors supporting its growth prospects.

Company

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea. Its core product is the Inspire system, an implantable neurostimulation therapy that monitors breathing during sleep and delivers mild hypoglossal nerve stimulation to help maintain an open airway. The company serves patients with moderate to severe obstructive sleep apnea who are seeking an alternative to traditional mask-based treatments, and its offerings are used in hospitals, ambulatory surgery centers, sleep centers, and ENT care pathways. Inspire Medical Systems operates in the United States and selected international markets, with a business centered on device commercialization, physician education, and related patient support services. The company is headquartered in Golden Valley, Minnesota, and remains a specialized player in the sleep medicine and neuromodulation markets.

CEO Mr. Timothy P. Herbert · 1,333 employees · United States · https://www.inspiresleep.com